Hsbc Holdings PLC Decreases Stake in DaVita Inc. (NYSE:DVA)

Hsbc Holdings PLC lessened its holdings in DaVita Inc. (NYSE:DVA) by 4.2% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 92,644 shares of the company’s stock after selling 4,076 shares during the period. Hsbc Holdings PLC owned approximately 0.11% of DaVita worth $12,855,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. 8 Knots Management LLC purchased a new position in DaVita in the fourth quarter worth $89,504,000. Doma Perpetual Capital Management LLC bought a new stake in shares of DaVita during the 4th quarter worth $53,076,000. Harvard Management Co. Inc. purchased a new position in shares of DaVita in the 2nd quarter worth about $55,115,000. Norges Bank bought a new position in DaVita during the fourth quarter valued at about $36,626,000. Finally, Allianz Asset Management GmbH increased its holdings in DaVita by 63.9% during the fourth quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after buying an additional 213,992 shares during the last quarter. 90.12% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 in the last three months. Corporate insiders own 2.00% of the company’s stock.

DaVita Stock Performance

Shares of DVA opened at $164.00 on Monday. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $166.04. The stock’s 50-day simple moving average is $147.64 and its 200 day simple moving average is $141.23. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. The stock has a market capitalization of $14.38 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 0.95 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. DaVita’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business earned $2.08 earnings per share. Research analysts forecast that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Analysts Set New Price Targets

DVA has been the subject of a number of research reports. UBS Group increased their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. TD Cowen increased their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Finally, Truist Financial upped their price objective on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $157.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.